BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches
Rhea-AI Summary
BioAdaptives (OTC: BDPT) announced completion of its commercial manufacturing and logistics supply chain, positioning the company to begin rolling out its next-generation wellness platforms starting next month. Over the past quarter, BioAdaptives secured standardized, high-quality raw materials and partnered with GMP-compliant manufacturing facilities to support anticipated demand.
The company is preparing launches for its MyndSystem cognitive performance platform, comprising MyndMed for daytime focus and memory and MyndRenew for overnight neurological recovery, and its Xcellara cellular wellness platform, which supports natural stem cell mobilization and is backed by human, double-blind, placebo-controlled clinical data. BioAdaptives plans to release detailed product specifications, launch timelines, and scientific dossiers in the coming weeks.
Positive
- Commercial supply chain readiness completed for upcoming wellness product launches
- GMP-compliant manufacturing partnerships and standardized raw material sourcing established
- Xcellara platform supported by human, double-blind, placebo-controlled clinical data on circulating stem and progenitor cells
Negative
- None.
News Market Reaction – BDPT
In the Jul 23 session, BDPT gained 7.69%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.
Over the past quarter, BioAdaptives has focused on securing high-quality, standardized raw materials and establishing partnerships with GMP-compliant manufacturing facilities. These steps ensure the company can meet anticipated market demand for its MyndSystem™ cognitive performance platform and its upcoming Xcellara™ cellular wellness products.
“Ultimately, our mission is driven by a deeper human truth: while the world focuses on living longer, our clients also want to live better,” said James Keener, Chief Executive Officer of BioAdaptives®. “Meaningful longevity means maintaining sharp cognitive function, physical vitality, and quality of life. That is what we are building toward with every formula we introduce.”
The company's dual-platform strategy addresses two rapidly growing global markets:
- The MyndSystem™ Platform: A 24-hour, stimulant-free, and WADA-compliant cognitive support system that helps maintain focus and memory during the day (MyndMed™) and promotes glymphatic clearance and neurological recovery overnight (MyndRenew™).
- The Xcellara™ Platform: A cellular wellness system that supports natural stem cell mobilization. The formulation is backed by human, double-blind, placebo-controlled clinical data showing a significant increase in circulating stem and progenitor cells, paired with targeted organic compounds.
BioAdaptives plans to release detailed product specifications, launch timelines, and scientific dossiers in the coming weeks. For more information, please visit MyndSystem.com and products.xcellara.com.
About BioAdaptives® Inc.
BioAdaptives, Inc. (OTC: BDPT) is a wellness and biotechnology company that develops and markets scientifically formulated, natural products that promote human and animal wellness. The company’s formulations are grounded in published and clinical research involving nutrition, stem cell biology, adaptogens, cellular transport mechanisms, and cellular health, with a focus on developing high-bioavailability health solutions that support normal physiological function.
Regulatory Disclaimer
These statements have not been evaluated by the Food and Drug Administration. Xcellara™ is a trademark of BioAdaptives® Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.
INVESTOR & MEDIA CONTACT
Emily Harrison
Investor Relations, BioAdaptives, Inc.
702-703-1233 | info@bioadaptives.com | www.bioadaptives.com
X – @BioAdaptivesInc
